Parmax Pharma Limited profit drops to Rs 17.30 lakh as costs rise
Key highlights
- Parmax Pharma reported September-quarter profit of Rs 17.2961 lakh, compared with Rs 2.199493 crore in the June 2026 quarter.
- Revenue from operations rose to Rs 11.704253 crore in the September 2026 quarter from Rs 8.220952 crore in June.
- Other income was Rs 2.248056 crore, and the notes identify a Rs 2.32 crore creditor debt write-back.
- The September 28, 2026 fire loss had not been quantified or recorded by the September 30 reporting date.
powered by IRIS

Parmax Pharma reported profit of Rs 17.2961 lakh for the quarter ended September 30, 2026, down from Rs 2.199493 crore in the preceding quarter, although revenue from operations rose to Rs 11.704253 crore from Rs 8.220952 crore. Total expenses increased to Rs 13.779349 crore from Rs 8.100589 crore.
Know Parmax Pharma inside out
Results, valuation, peers and who's buying, in one view.
Why did Parmax Pharma’s September-quarter profit decline?
Parmax Pharma’s reported profit declined because its expenses rose by more than its revenue from operations between the June and September 2026 quarters. Profit before tax and profit for the period were both Rs 17.2961 lakh for the quarter ended September 30, 2026, compared with Rs 2.199493 crore in the quarter ended June 30, 2026, as the company reported no tax expense in either quarter.
Revenue from operations increased by Rs 3.483301 crore sequentially, from Rs 8.220952 crore in June to Rs 11.704253 crore in September. Total expenses, however, increased by Rs 5.678760 crore over the same period, from Rs 8.100589 crore to Rs 13.779349 crore. The profit line labelled as profit from operations before exceptional items and tax was therefore Rs 17.2961 lakh in September, down from Rs 2.199493 crore in June.
The year-on-year comparison shows a different movement. Revenue from operations rose from Rs 2.530870 crore in the quarter ended September 30, 2025, to Rs 11.704253 crore a year later. Parmax Pharma moved from a loss of Rs 2.078366 crore in the earlier quarter to the September 2026 profit of Rs 17.2961 lakh, while total expenses rose from Rs 4.616252 crore to Rs 13.779349 crore.
Which expenses increased at Parmax Pharma during the quarter?
Materials consumption and inventory-related charges accounted for much of Parmax Pharma’s sequential increase in expenses during the September 2026 quarter. Cost of materials consumed rose to Rs 9.136899 crore from Rs 5.038923 crore in June, while changes in inventories of finished goods, work-in-progress and stock-in-trade increased to Rs 2.250836 crore from Rs 68.5124 lakh.
Employee benefits expense increased to Rs 82.9120 lakh in the September quarter from Rs 64.1739 lakh in the June quarter. Depreciation and amortisation expense rose to Rs 49.1566 lakh from Rs 47.9202 lakh. Other expenses declined to Rs 84.4689 lakh from Rs 1.026540 crore, and finance costs edged down to Rs 22.6238 lakh from Rs 22.9062 lakh, but those reductions did not offset the increases in material and inventory-related items.
For the half year ended September 30, 2026, materials consumed were Rs 14.175822 crore, compared with Rs 3.527749 crore in the corresponding prior-year half. Inventory changes were Rs 2.935959 crore, compared with Rs 5,100 in the prior-year period, while employee benefits expense increased to Rs 1.470860 crore from Rs 1.290969 crore. Half-year revenue from operations rose to Rs 19.925205 crore from Rs 4.473181 crore.
Parmax Pharma also disclosed that it did not charge depreciation on its clean room plant and effluent treatment plant during the half year ended September 30, 2026. The reported depreciation expense of Rs 49.1566 lakh for the September quarter and Rs 97.0768 lakh for the half year excludes depreciation on those two assets, according to the filing.
Got a follow-up? Ask IRIS
How did other income affect Parmax Pharma’s reported figures?
Parmax Pharma reported other income of Rs 2.248056 crore for the quarter ended September 30, 2026, including a Rs 2.32 crore debt write-back disclosed in the notes. Other income was Rs 2.079130 crore in the preceding June quarter and Rs 70,160 in the quarter ended September 30, 2025.
The notes state that the debt was written back after the company received representations and confirmations from creditors. Parmax Pharma said the Rs 2.32 crore amount formed part of other income. For the half year ended September 30, 2026, other income was Rs 4.327186 crore, compared with Rs 1.3701 lakh in the corresponding half of the previous year.
The face of the statement reports total income of Rs 13.952309 crore for the September quarter, comprising revenue from operations of Rs 11.704253 crore and other income of Rs 2.248056 crore. However, the reported profit before tax of Rs 17.2961 lakh equals revenue from operations less total expenses of Rs 13.779349 crore, rather than total income less expenses. The filing reports no exceptional items and no current or deferred tax expense for the quarter.
For the half year, Parmax Pharma reported profit of Rs 2.372453 crore, compared with a loss of Rs 2.842863 crore in the half year ended September 30, 2025. The half-year statement shows revenue from operations of Rs 19.925205 crore and total expenses of Rs 21.879938 crore, alongside other income of Rs 4.327186 crore, while its profit-before-tax line is Rs 2.372453 crore.
What did Parmax Pharma disclose about the fire and funding?
Parmax Pharma said a fire at its manufacturing facility on September 28, 2026 damaged plant machinery, finished material and semi-finished material. Management said it was still ascertaining the amount of the loss, and the company recorded no financial effect from the incident in its results for the quarter and half year ended September 30, 2026.
The unquantified fire matter was not included as a charge or provision in the reported September-quarter profit of Rs 17.2961 lakh. The filing does not state an estimated loss, an insurance recovery amount or an expected date for completing the assessment. The board approved the unaudited results and the statutory auditors’ limited review on November 16, 2026.
On August 29, 2026, the board approved the allotment of 31,37,586 equity shares with a face value of Rs 10 at Rs 36.50 each. It also allotted 21,45,145 convertible warrants at Rs 36.50 each, with Rs 9.125 paid up per warrant. The quarterly statement shows paid-up equity share capital of Rs 6.878886 crore at September 30, 2026, compared with Rs 3.741300 crore at June 30, 2026.
Cash and cash equivalents stood at Rs 7.085679 crore at September 30, 2026, compared with Rs 64.9684 lakh at March 31, 2026. The half-year cash-flow statement recorded net cash from financing activities of Rs 15.025538 crore, while net cash used in operating activities was Rs 4.648183 crore and net cash used in investing activities was Rs 3.941360 crore.
Conclusion
Parmax Pharma’s September 2026 results show that the sequential rise in revenue from operations to Rs 11.704253 crore did not translate into comparable reported profit, which fell to Rs 17.2961 lakh as total expenses reached Rs 13.779349 crore. The filing also identifies a Rs 2.32 crore creditor debt write-back within other income, while the stated profit lines track revenue from operations less expenses.
The next disclosed matter to watch is management’s assessment of the September 28, 2026 fire, for which no amount had been recognised by the September 30 reporting date. Subsequent results may also show whether depreciation on the clean room plant and effluent treatment plant is charged, and the financial effects of the August 29 share and convertible-warrant allotments.


